The presence of Hsp90 autoantibodies in patients with late stage ovarian cancer [119,126], breast cancer [127], and osteosarcoma [128] lends further support to tumor-derived circulating Hsp90. This evidence concerns the gene HSP90AA1 and neoplasm.